Materias dentro de su búsqueda.
Mostrando 1,661 - 1,680 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.24s Limitar resultados
  1. 1661
    “…Here, we aimed to test the hypothesis that combined inhibition of EGFR, HER2, and HER3 signalling with the tyrosine kinase inhibitor AZD8931 will control growth of all wild-type tumours. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
  2. 1662
    “…The HER2 oncogene and its truncated form p95HER2 play central roles in breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503
  3. 1663
    “…Purpose: As well as functioning as a ligand that is selectively internalized by cells overexpressing human epidermal growth factor receptor-2 (HER2), HApt can exert cytotoxic effects by inducing cross-linking and subsequent translocation of HER2 to cytoplasmic vesicles, such downregulation of HER2 inhibits cell proliferation and induces apoptosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells
  4. 1664
    “…Amplification and/or overexpression of human epidermal growth factor receptor 2 (HER2) are observed in 15–20% of breast cancers (HER2+ breast cancers), and anti-HER2 therapies have significantly improved prognosis of patients with HER2+ breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
  5. 1665
    “…METHODS: Immunohistochemical status of pHER2(Y1248), EGFR/HER1, HER3, and HER4 was determined in 124 consecutive HER2-positive BC patients (median age [range] = 57 years [49.0-64.0]) treated at the University Hospital for Tumors, Zagreb, between 2008 and 2011. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients
  6. 1666
    “…Introduction HER2 positivity is one of the most important predictive factors in the treatment of breast cancer patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
  7. 1667
    por Ordan, Julien
    Publicado 2019
    “…Visit by Her Excellency Ms Ana Rosa Valdivieso Santa María Ambassador of Peru to Switzerland and Liechtenstein…”
    Enlace del recurso
    Her Excellency Ms Ana Rosa Valdivieso Santa María Ambassador of Peru to Switzerland and Liechtenstein
  8. 1668
    por Kuznetsov, V B, Nijhoff, F W
    Publicado 2001
    Enlace del recurso
    Workshop on Mathematical Methods of Regular Dynamics : Festschrift Kowalevski (Sophie) on her 150th Birthday
  9. 1669
    por CERN Press Office. Geneva
    Publicado 1985
    Enlace del recurso
    Her majesty Queen Beatrix and his royal highness Prince Claus of the Netherlands visit CERN
  10. 1670
    por CERN Press Office. Geneva
    Publicado 1985
    Enlace del recurso
    Her majesty Queen Beatrix and his royal highness Prince Claus of the Netherlands visited CERN
  11. 1671
    “…SIMPLE SUMMARY: Novel antibody-drug conjugates (ADCs) show efficacy in advanced breast cancer with low HER2 levels. Little is known about the discordance of low HER2 levels between the primary tumor and distant metastases. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
  12. 1672
    “…BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients continue to progress despite multiple anti-HER2-targeted treatments. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis
  13. 1673
    “…Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR(+)/HER2(−)) tumours are the most frequent subtype with a similar incidence to that observed amongst recurrent MBC (rMBC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HR(+)/HER2(−) de novo metastatic breast cancer: a true peculiar entity?
  14. 1674
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
  15. 1675
    “…SIMPLE SUMMARY: HER2-equivocal cases represent around 15% of breast carcinomas, and 20–40% of them are HER2-amplified. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases
  16. 1676
    “…BACKGROUND: Brain metastases (BM) are common among HER2+ breast cancer (BC) and prognostic stratification is crucial for optimal management. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
  17. 1677
    “…Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
  18. 1678
    “…Human epidermal growth factor receptor 2 (HER2) is overexpressed in various cancer types. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers
  19. 1679
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    ‘I bring her up with love:’ Perspectives of caregivers of children with neurodevelopmental delays in western Kenya
  20. 1680
    “…Activation of HER2/ErbB2 coincides with escape from ductal carcinoma in situ (DCIS) premalignancy and disrupts 3D organization of cultured breast-epithelial spheroids. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Nucleocytoplasmic transport of active HER2 causes fractional escape from the DCIS-like state
Herramientas de búsqueda: RSS